Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Open-label extension of BIBF 1120 in idiopathic pulmonary fibrosis
CTR20131473Phase 3Completed
- Sponsor
- Boehringer Ingelheim
- Start
- Sep 2014
- Modality
- Small Molecules
- Countries
- 1
01
Overview
A Phase 3 trial of nintedanib in idiopathic pulmonary fibrosis (IPF), sponsored by Boehringer Ingelheim. Started Sep 2014; status: completed.
02
Drugs
nintedanib
03
Conditions
idiopathic pulmonary fibrosis (IPF)
Beyond the preview
Go deeper on CTR20131473.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on CTR20131473.